Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II

Published:2024-08 Issue: Volume:200 Page:104385
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Ferrer Florent,Tetu Pauline,Dousset Léa,Lebbe Céleste,Ciccolini Joseph,Combarel David,Meyer Nicolas,Paci Angelo,Bouchet Stéphane

Funder

Pierre Fabre Médicament Centre de Développement Clinique et Oncologie

Publisher

Elsevier BV

Reference116 articles.

1. 202570orig1s000clinpharmr.pdf, n.d.

2. Improving the tolerability of osimertinib by identifying its toxic limit;Agema;Ther. Adv. Med. Oncol.,2022

3. The safety of afatinib for the treatment of non-small cell lung cancer;Barron;Expert Opin. Drug Saf.,2016

4. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer;Bender;Oncol. Nurs. Forum,2014

5. Without therapeutic drug monitoring, there is no personalized cancer care;Beumer;Clin. Pharmacol. Ther.,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP